Related to PAR-19-040

Title	Announcement Number	Related	Issuing Org	Release Date	Opening Date	Expiration Date	Activity Code
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)	PAR-19-040		NINDS	10-26-2018	08-10-2019	09-15-2021	U01
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)	PAR-16-331	Related Link	NINDS	06-15-2016	08-13-2016	09-12-2018	U01
Countermeasures Against Chemical Threats (CounterACT): Opportunities in Opioid Research	NOT-NS-18-019	Related Link	NINDS	11-27-2017
Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)	PAR-18-657	Related Link	NINDS	02-13-2018	08-11-2018	10-09-2020	U54
Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)	PAR-18-721	Related Link	NINDS	03-28-2018	04-30-2018	07-01-2020	R21
Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)	PAR-19-039	Related Link	NINDS	10-26-2018	08-10-2019	09-15-2021	U01
Notice of Special Interest: Administrative Supplements to Promote and Expand into the Research and Development of Medical Countermeasures Against Chemical Threats	NOT-NS-20-030	Related Link	NINDS	01-06-2020		08-04-2020	(Admin Supp)
Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)	PAR-20-253	Related Link	NINDS	07-07-2020	04-26-2021	05-31-2023	R21
Notice of Change to Key Dates for PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)"	NOT-NS-20-088	Related Link	NINDS	07-10-2020
Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)	PAR-20-316	Related Link	NINDS	12-21-2020	08-14-2021	09-13-2023	U54
Notice of NIAID's Participation in PAR-19-040: Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)	NOT-AI-21-027	Related Link	NIAID	01-29-2021